Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

Roche and Synosis Form CNS Partnership

  • Synosis Therapeutics acquired five drug candidates targeting the central nervous system from Roche. Of the five Roche-discontinued compounds are Phase I molecules. "By partnering with Synosis, we're giving these potential medicines the best chance of success by creatively extending our innovation base in an important therapeutic area," comments Peter Hug, Roche's global head of Pharma Partnering.

    Under the terms of the deal, Synosis will be responsible for the clinical development of all five candidates. Roche retains the right to opt-in to two preselected programs. Synosis has full commercial rights to three preselected programs.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »